FDA Approves Inavolisib with Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-mutated, HR-positive, HER2-negative Advanced Breast Cancer By Ogkologos - November 20, 2024 742 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the INAVO120 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Treatment Guided by Comprehensive Genomic Profiling and Expert MTB Decision-Making Improves... October 14, 2025 Socioeconomic Deprivation Associated with Worse Survival in Patients with Cancer Included... March 23, 2021 Extended Anticoagulation with Reduced-Dose Non-inferior to Full-Dose Apixaban for the Prevention... April 29, 2025 Lighting Ceremony at Lincoln Memorial Honors the 400,000 Lives Lost to... January 20, 2021 Load more HOT NEWS ΚΑΡΚΙΝΟΣ ΤΟΥ ΝΕΦΡΟΥ Patient Guide in Testicular Cancer Now Available Also in Italian The Power of Fruits and Vegetables What to Know About the Different Types of Mastectomies for Breast...
